Biomarin Pharmaceutical (BMRN) Other Accumulated Expenses (2010 - 2015)

Biomarin Pharmaceutical has disclosed Other Accumulated Expenses across 6 years of filings, most recently posting $9.5 million for Q2 2015.

• Quarterly Other Accumulated Expenses rose 161.81% year-over-year to $9.5 million in Q2 2015, while the trailing twelve-month figure through Jun 2015 was $9.5 million (up 161.81% YoY) and the FY2014 annual result came in at $8.2 million, up 69.11% from the prior year.
• Other Accumulated Expenses improved to $9.5 million in Q2 2015, from $8.7 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $13.3 million in Q1 2012 and troughed at $1.4 million in Q2 2013.
• A 5-year average of $6.4 million and a median of $6.0 million in 2011 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2013 — Other Accumulated Expenses slumped 81.46% — and 2014, when it soared 165.66%.
• Tracing BMRN's Other Accumulated Expenses over 5 years: stood at $9.3 million in 2011, then plunged by 33.26% to $6.2 million in 2012, then slipped by 21.1% to $4.9 million in 2013, then jumped by 69.11% to $8.2 million in 2014, then increased by 14.99% to $9.5 million in 2015.
• Business Quant data shows BMRN's Other Accumulated Expenses at $9.5 million in Q2 2015, $8.7 million in Q1 2015, and $8.2 million in Q4 2014.